Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
24 Aug 2021
24 Aug 2021
Historique:
received:
14
01
2021
accepted:
12
07
2021
entrez:
25
8
2021
pubmed:
26
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Influenza immunization protects seniors against influenza and its potentially serious complications. It is uncertain whether standard-dose (SD) quadrivalent vaccine offers better protection over other formulations in the elderly. In this study, we compared the effectiveness of SD-trivalent, high-dose (HD) trivalent, SD-quadrivalent, and adjuvanted trivalent vaccines in seniors (≥65 years) in a real-world setting. We selected over 200,000 individuals in each of 6 influenza seasons from 2012 to 2018 using MarketScan® databases. The two outcomes were hospitalization or emergency room (ER) visit due to (1) influenza or (2) pneumonia. Here, SD-quadrivalent was associated with higher risk of influenza-related hospitalization/ER visit (adjusted hazard ratio (aHR) 1.14 and 95% confidence interval (95% CI) 1.05-1.24) and of pneumonia-related hospitalization/ER visit (aHR 1.04 and 95% CI 1.01-1.07) vs. HD-trivalent. SD-trivalent followed similar trends compared to HD-trivalent (aHR 1.16 and 95% CI 1.06-1.27 for hospitalized/ER visit influenza; aHR 1.07 and 95% CI 1.05-1.10 for hospitalized/ER visit pneumonia). We could not demonstrate risk differences between SD vaccine formulations and between adjuvanted trivalent and one of the other three vaccines. Risk estimates slightly varied across seasons. These findings suggest that SD vaccine formulations vs. HD-trivalent were associated with higher risk of hospitalization/ER visit for influenza and pneumonia in seniors.
Identifiants
pubmed: 34429431
doi: 10.1038/s41541-021-00373-w
pii: 10.1038/s41541-021-00373-w
pmc: PMC8385076
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108Subventions
Organisme : Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
ID : TD3-137716
Informations de copyright
© 2021. The Author(s).
Références
J Infect Dis. 2018 May 5;217(11):1718-1727
pubmed: 29452380
Vaccine. 2020 Sep 29;38(42):6562-6569
pubmed: 32800465
Vaccine. 2013 Dec 9;31(51):6122-8
pubmed: 23933368
MMWR Recomm Rep. 2020 Aug 21;69(8):1-24
pubmed: 32820746
Clin Infect Dis. 2021 Mar 15;72(6):995-1003
pubmed: 32067049
Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):59-66
pubmed: 25335470
J Infect Dis. 2017 Feb 15;215(4):510-517
pubmed: 28329311
Am J Epidemiol. 2012 Sep 15;176(6):527-33
pubmed: 22940713
JAMA. 2021 Jan 5;325(1):39-49
pubmed: 33275134
Euro Surveill. 2020 May;25(19):
pubmed: 32431290
Clin Infect Dis. 2015 Jul 15;61(2):171-6
pubmed: 25829001
J Infect Dis. 2019 Sep 13;220(8):1255-1264
pubmed: 30561688
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098
Vaccine. 2017 Jan 23;35(4):513-520
pubmed: 28024956
Expert Rev Vaccines. 2018 May;17(5):435-443
pubmed: 29715054
Lancet Infect Dis. 2015 Mar;15(3):263
pubmed: 25749223
Expert Rev Vaccines. 2019 Jun;18(6):663-670
pubmed: 31155968
J Infect Dis. 2019 Sep 26;220(9):1511-1520
pubmed: 31290553
Vaccine. 2017 May 15;35(21):2775-2780
pubmed: 28431815